AUG 06, 2016 2:04 PM PDT

New Immunotherapy Strategy Against Lymphoma

WRITTEN BY: Xuan Pham
In an effort to nip lymphomas before it becomes lethal to patients, scientists at the University of Geneva have developed a new way to block the cancer’s migration. This process locks the cancer cells and prevents spread to the lymphatic system.

Blocking the migration of cancer cells to destroy them | Image: University of Geneva
 
Cancer of the blood can be a frightening diagnosis. Lymphomas occur when lymphocytes (white blood cells) turn malignant. It usually starts in a lymphoid organ, such as the lymph node, spleen, or bone marrow, and then infiltrates other organs and tissues. The Leukemia and Lymphoma Society estimates that over 81,000 new patients will be diagnosed with lymphoma this year in the U.S.
 
Malignant lymphocytes become dangerous when they circulate in the blood and travel to the lymphatic system. There, the cancerous cells can cause swelling of the lymph nodes and disrupt normal metabolic processes.
 
But before they arrive at the lymph system, scientists say the cancerous lymphocytes are not yet dangerous. “Since they cannot survive in the blood for long, these malignant cells are compelled to find a more accommodating environment - such as the lymphatic system - where they can proliferate,” said Thomas Matthes, professor at the University of Geneva and senior study author. “We decided to focus on this Achilles heel by containing them in the blood so as to prevent any resulting harm,” he further explained.
 

 Indeed, the team learned that cancerous lymphocytes leave the confines of the blood vessels by expressing a surface protein known as JAM-C. This protein acts like a pass, allowing the mutant cells to get through the endothelial cells that line blood vessels.
 
The team then developed an antibody against JAM-C. This protein targets JAM-C and essentially makes the surface protein unrecognizable to the endothelial cell guards. Essentially, the antibody, named H225, revoked the mutant cells’ ability to migrate out of blood vessels.
 
In experiments, the team showed H225 decreased the cancer cells’ migration to the lymphs by over 50 percent. “H225 also significantly limited cell proliferation, even when tumor cells had already settled in the lymphatic system. In our mice, we observed the nearly-complete disappearance of already-present tumor cells in the organs,” Matthes added.
 
There are nearly 790,000 people currently living with, or recovering from, lymphoma in the U.S. The survival rate from lymphoma is increasing, but only thanks to new research such as this that exploit the cancer’s weaknesses to patients’ advantage. 

Additional source: University of Geneva press release
 
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 29, 2021
Cancer
Shorter radiation course effective for men with high-risk prostate cancer
JAN 29, 2021
Shorter radiation course effective for men with high-risk prostate cancer
Could shortening radiation courses for men undergoing treatment for prostate cancer be just as effective as conventional ...
FEB 18, 2021
Cancer
Measuring the psychological impacts of cancer and additional comorbidities
FEB 18, 2021
Measuring the psychological impacts of cancer and additional comorbidities
In a new analysis of 2017 data from the National Health Survey of Spain published in Psycho-Oncology, researchers find t ...
FEB 19, 2021
Cancer
Deep learning helps predict lung cancer
FEB 19, 2021
Deep learning helps predict lung cancer
A study from Penn State Great Valley researchers describes how a deep learning model could be used to predict the surviv ...
MAR 18, 2021
Cancer
Could electricity impede cancer metastasis?
MAR 18, 2021
Could electricity impede cancer metastasis?
New research published in the journal Bioelectricity suggests that electricity and electromagnetic fields may deter the ...
APR 03, 2021
Cancer
New factor plays a key role in immune response
APR 03, 2021
New factor plays a key role in immune response
In a study published recently in Science Immunology, WEHI’s Professor Stephen Nutt, Dr. Michael Chopin, and Mr. Sh ...
APR 08, 2021
Cancer
What can modifiying cultured cells to act more like normal cells teach us about cancer?
APR 08, 2021
What can modifiying cultured cells to act more like normal cells teach us about cancer?
A team from the University of Louisville has developed a technique to make cell cultures act more like normal cells. Thi ...
Loading Comments...